Medically reviewed by Lindsay Cook, PharmDHuman epidermal growth factor receptor 2 (HER2) proteins are found on the surface of breast cells and are involved in normal cell growth. Too much HER2 ...

Medicaid expansion was associated with a slower decrease in receipt of guideline-concordant treatment, reduced delays in treatment initiation, and improved 2-year survival, according to researchers.

Thanks to these treatments, five-year survival rates for people with HER2-positive metastatic breast cancer who are hormone-receptor positive are slightly higher than those who are negative. The goal ...

The women had early stage breast cancer that was HR-positive and HER2-negative. When compared ... the overall 5-year relative survival rate for breast cancer is 91.2%. If the tumor is still ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Dispelling myths around breast cancer in Africa is important so that treatment care can focus on the dire socio-economic ...

Medicaid expansion improved 2-year survival rates and access to guideline-concordant treatment for patients with HR-negative and HER2-positive breast cancer. The study highlights the role of ...

"Breast cancer is far too common, and rates are increasing among ... With Timely Receipt of Treatment and Survival Among Patients With HR-Negative, HER2-Positive Breast Cancer, Journal of the ...

Vyloy plus standard-of-care chemotherapy extended overall survival in patients with advanced gastric cancer. The rate of ...

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Genentech, a member ...

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...